Management Team

Our management team has a proven track record of successfully developing and commercializing pharmaceuticals while maintaining a distinct focus on efficient, entrepreneurial business processes.

Michael Macaluso, Chairman and Chief Executive Officer

Michael Macaluso founded DMI Life Sciences, Inc., our predecessor, and has been a member of the board of directors of DMI Life Sciences, Inc. since its inception. Mr. Macaluso has also been a member of our Board of Directors since the merger with Chay Enterprises in March 2010, our Chief Executive Officer since January 9, 2012 and the Chairman of our Board of Directors since May 2010. In addition, Mr. Macaluso has served as the Chairman of Aytu BioScience’s (AYTU) Compensation Committee since 2019. Mr. Macaluso was appointed President of Isolagen, Inc. (ILE) and served in that position from June 2001 to August 2001, when he was appointed Chief Executive Officer. In June 2003, Mr. Macaluso was re-appointed as President of Isolagen and served as both Chief Executive Officer and President until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005. From October 1998 until June 2001, Mr. Macaluso was the owner of Page International Communications, a manufacturing business. Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from 1989 until 1997, when he sold that business to a private equity firm. Mr. Macaluso’s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities and corporate finance led to the conclusion of our Board of Directors that he should serve as a director of our company in light of our business and structure.

Holli Cherevka, Chief Operating Officer

Holli joined Ampio Pharmaceuticals in 2013, and prior to taking her current role, she served as the company’s vice president of operations and oversaw clinical, regulatory and manufacturing operations. She has held roles of increasing responsibility throughout her career including site leadership, strategic planning, contractor management, and product portfolio leadership.

Previously, Holli was the Director of Business Development at the American College of Radiology (ACR) Image Metrix. Holli earned a Bachelor of Arts from California State University, Chico, and holds a Master’s of Science in Biomedical and Molecular Sciences Research from King’s College, London.

Holli is a member of the Parenteral Drug Association, Colorado Bioscience Association and the International Society of Pharmaceutical Engineers, and has represented Ampio Pharmaceuticals at conferences for the International Society of Pharmaceutical Engineers as well as at Global Investment Conferences.

Dan Stokely, Chief Financial Officer

Daniel G. Stokely has more than 30 years of experience in finance and accounting. Daniel began his career at Deloitte & Touche and since that time, he has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Most recently, since 2012, Daniel served as Executive Vice President and Chief Financial Officer of Sentynl Therapeutics Inc., a privately-held specialty pharmaceutical company focused on in-licensing, acquisition, marketing and distribution of development stage and commercially marketed prescription pain products, which was sold to Cadila Healthcare Ltd. in January 2017. From 2004 to 2012, Daniel served as Vice President of Finance and Chief Accounting Officer of Victory Pharma, a privately-held specialty pharmaceutical company focused on in-licensing, internal product development, marketing and distribution of pain specialty products, which was sold to Shionogi, Inc., a Japanese pharmaceutical company, in 2011. From 2001 to 2004, Daniel served as the Corporate Controller and Chief Accounting Officer for Wireless Facilities, Inc. (currently Kratos Defense & Security Solutions), a publicly traded, global provider of communications and security services for the wireless communications industry. From 1994 to 2001, Daniel served as Corporate Controller of Dura Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Elan Pharmaceuticals in late 2000. Daniel has a bachelor’s degree in accounting from San Diego State University and is a Certified Public Accountant (licensed in California).

Management Team

Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients

AMPIO RECEIVES FEEDBACK FROM THE FDA ON AMPIO’S PROPOSED MODIFICATIONS TO THE SPECIAL PROTOCOL ASSSESSMENT FOR AMPION TREATMENT OF SEVERE OSTEOARTHRITIS OF THE KNEE

Management Team

Ampion regulates the immune response